Literature DB >> 6268732

Characteristics of Epstein-Barr virus activation of human B lymphocytes.

A G Bird, S Britton, I Ernberg, K Nilsson.   

Abstract

Epstein-Barr virus (EBV) will infect at least every third cell if exposed in vitro to an extensively purified B cell population from human peripheral blood. About 10% of such infected cells will be driven into immunoglobulin synthesis and secretion, as judged by the indirect protein A plaque assay. The appearance of EB nuclear antigen, de novo DNA synthesis, and immunoglobulin secretion are linked phenomena accompanying infection as judged by viral dilution experiments, which yield kinetics of a one-hit order. Induction of immunoglobulin secretion in B cells by EBV requires de novo synthesis of DNA, and consequently, nontransforming EBV (P3HR1) will not induce immunoglobulin secretion and will also specifically block such induction from subsequently added EBV. The termination of immunoglobulin induction by EBV in short-term cultures appears to be T cell dependent.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6268732      PMCID: PMC2186459          DOI: 10.1084/jem.154.3.832

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

1.  A live human B-cell activator operating in isolation of other cellular influences.

Authors:  A G Bird; S Britton
Journal:  Scand J Immunol       Date:  1979       Impact factor: 3.487

Review 2.  A new approach to the study of human B lymphocyte function using an indirect plaque assay and a direct B cell activator.

Authors:  A G Bird; S Britton
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

3.  Induction of EBNA precedes the first cellular S-phase after EBV-infection of human lymphocytes.

Authors:  L Einhorn; I Ernberg
Journal:  Int J Cancer       Date:  1978-02-15       Impact factor: 7.396

4.  Inhibition of DNA metabolism in human B lymphocytes by a substrain of Epstein-Barr virus (P3HR-1): a method for virus quantitation.

Authors:  M Steinitz; T Bakács; E Yefenof; G Klein
Journal:  Intervirology       Date:  1978       Impact factor: 1.763

5.  Epstein-Barr virus (EBV) receptors, complement receptors, and EBV infectibility of different lymphocyte fractions of human peripheral blood. II. Epstein-Barr virus studies.

Authors:  L Einhorn; M Steinitz; E Yefenof; I Ernberg; T Bakacs; G Klein
Journal:  Cell Immunol       Date:  1978-01       Impact factor: 4.868

6.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

Review 7.  Various forms of Epstein-Barr virus infection in man: established facts and a general concept.

Authors:  M A Epstein; B G Achong
Journal:  Lancet       Date:  1973-10-13       Impact factor: 79.321

8.  Activation to IgG secretion by lipopolysaccharide requires several proliferation cycles.

Authors:  E S Gronowicz; C Doss; J Schröder
Journal:  J Immunol       Date:  1979-11       Impact factor: 5.422

9.  Comparative studies on adult donor lymphocytes infected by EB virus in vivo or in vitro: origin of transformed cells arising in co-cultures with foetal lymphocytes.

Authors:  A B Rickinson; S Finerty; M A Epstein
Journal:  Int J Cancer       Date:  1977-06-15       Impact factor: 7.396

10.  Comparison of the yield of infectious virus from clones of human and simian lymphoblastoid lines transformed by Epstein-Barr virus.

Authors:  G Miller; M Lipman
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  24 in total

1.  Autocrine models of B-lymphocyte growth. I. Role of cell contact and soluble factors in T-independent B-cell responses.

Authors:  J Gordon; G Guy; L Walker
Journal:  Immunology       Date:  1985-10       Impact factor: 7.397

2.  A routine method for the establishment of permanent growing lymphoblastoid cell lines.

Authors:  H Neitzel
Journal:  Hum Genet       Date:  1986-08       Impact factor: 4.132

3.  An efficient method for routine Epstein-Barr virus immortalization of human B lymphocytes.

Authors:  F E Wall; R D Henkel; M P Stern; H B Jenson; M P Moyer
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-02       Impact factor: 2.416

4.  Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation.

Authors:  B Tomkinson; E Robertson; E Kieff
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

5.  Epstein-Barr virus recombinants from overlapping cosmid fragments.

Authors:  B Tomkinson; E Robertson; R Yalamanchili; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.

Authors:  E S Robertson; B Tomkinson; E Kieff
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

8.  Rescue of IgM, IgG, and IgA production in common varied immunodeficiency by T cell-independent stimulation with Epstein-Barr virus.

Authors:  G Jeong; P Ralph; I Nakoinz; O Saiki; C Cunningham-Rundles
Journal:  J Clin Immunol       Date:  1985-03       Impact factor: 8.317

9.  Epstein-Barr virus-transformed lymphocytes produce monoclonal autoantibodies that react with antigens in multiple organs.

Authors:  C Garzelli; F E Taub; J E Scharff; B S Prabhakar; F Ginsberg-Fellner; A L Notkins
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

10.  Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.

Authors:  Vahid Younesi; Forough Golsaz Shirazi; Ali Memarian; Amir Amanzadeh; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2013-02-13       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.